Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases

Abstract

Aim: To identify changes in the biochemical and biophysical behavior of lung surfactant (LS) in the unventilated and ventilated lung during surgery in patients with nonsmall cells lung cancer (NSCLC). The relationship between the surfactant changes and complications was examined.Material and Methods: In prospective study we included 32 patients (SG) with NSCLC and a control group(CG) of 29 patients without cancer. Surgery was performed under general anesthesia and a double lumen tube intubation. In both groups we performed bronchoalveolar lavage (BAL): A. From the operated (nonventilated) lung after intubation and before reventilation; B. From ventilated lung after intubation and at the end of anestesia. Biochemical analysis: the amount of phospholipids, cholesterol and proteins. Biophysical analysis: the equilibrium surface tension(g_eq) and dynamic characteristics of monolayers (minimal surface tension g_min, maximal surface tension, g_max).Results: In SG the amount of LS phospholipids was significantly lower, as compared to the CG (70.4 vs. 219.2 µg/mg protein). In addition, we detected an increase in the amount of the LS proteins (mg/ml) in the second samples of both lungs: ventilated (0.13 vs. 0.42) and nonventilated(0.23 vs. 0.47). We noticed a deterioration of g_eq in cancer patients as compared to the CG (43.11 vs. 29.4 mN/m). g_min was increased in the second samples: ventilatedlung (10.98 vs. 14.3 mN/m) and unventilatedlung (9.65 vs. 17.69 mN/m). Respiratory postoperative complications were observed - hypoventilation in 8 patients , pneumonia - in 3.Conclusion: Lung cancer patients have changed behavior of LS. Hypoxia and inhalation anesthesia affects the biochemical and biophysical properties of LS.

Rating:

Share or cite this content

Citations should be made in the following way:
Y. Yamakova, R. Petkov, M. Bangyozova, A. Jordanova, A. Tsanova, Z. Lalchev, V. Ilieva, V. Stenev (Sofia, Bulgaria). Surfactant changes in patients with lung cancer underwent to resection. Eur Respir J 2014; 44: Suppl. 58, 3880

Member's Comments

No comment yet.

Related content which might interest you: Cytotoxic phenotype of alveolar lymphocytes (AL) in bronchoalveolar lavage fluid (BALF) from non-small cell lung cancer (NSCLC) patients Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Evaluation of IL-33 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Serum and bronchial aspiration fluid HE-4 levels in lung cancer Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Feroptosis of alveolar macrophages in lung cancer Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Evaluation of IL-10 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Visible tumour on bronchoscopy: Do we need cytology? Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Inflammasome pathway activation in patients with non-small cell lung cancer (NSCLC): A bronchoalveolar lavage fluid study Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer Year: 2013 The value of bacterial culture in patients with suspected lung cancer evaluated by bronchoscopy: A prospective study of 155 patients Source: International Congress 2014 – Cells, biofilms and biomarkers in respiratory infections Year: 2014 Decreased apoptosis rate of alveolar lymphocytes (AL) in patients with stage I-IIA non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 The level of bronchoalveolar lavage fluid prostaglandine E2; Is it diagnostic of bronchogenic carcinoma? Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Matrix metalloproteinase-9 (MMP-9) elevated in serum, but not in bronchial lavage in lung cancer patients Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Bronchoscopic semantics and diagnosis of lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Utility of bronchoalveolar lavage in the determination of lung asbestos burden in Barcelona, Spain Source: Annual Congress 2013 –Environmental and occupational respiratory diseases: new exposure assessment methods, experimental exposure in animal and humans and mechanisms Year: 2013 Lymphocyte profile in the BALF from affected lung in comparison to healthy lung and systemic inflammation in lung cancer Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Survival of non small cell lung carcinoma patients with malignant pleural effusions Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Microparticles as biomarkers of lung injury in human broncho-alveolar lavage fluid Source: International Congress 2014 – Translational studies in COPD Year: 2014 Increased expression of WSX1 on alveolar lymphocytes (AL) in patients with early stage non-small cell lung cancer (NSCLC). Preliminary report Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Lung cancer patients survival after laser resection Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Detection of exosomal miRNA in pulmonary sarcoidosis Source: International Congress 2014 – Novel epigenetic regulators for targeting via nanomedicine Year: 2014 Evaluation of response to chemotherapy with fiberoptic bronchoscopy in lung cancers Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016